Longitudinal Measurements of Flow in Cerebrospinal Fluid Shunts With a Wireless Thermal Anisotropy Measurement Device

Sponsor
Rhaeos, Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06086561
Collaborator
(none)
30
1
4

Study Details

Study Description

Brief Summary

This study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (CSF) shunt flow. Patients with an existing implanted shunt will wear the device to acquire longitudinal data.

Condition or Disease Intervention/Treatment Phase
  • Device: Thermal Anisotropy Measurement Device
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Longitudinal Measurements of Flow in Cerebrospinal Fluid Shunts With a Wireless Thermal Anisotropy Measurement Device
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Feasibility Assessment Cohort

Non-invasive device data acquisition; study is not interventional

Device: Thermal Anisotropy Measurement Device
The study device is a non-invasive sensor that is placed on the study subject's skin overlying an existing implanted CSF shunt. It uses an integrated thermal actuator and temperature sensors to assess shunt flow.

Outcome Measures

Primary Outcome Measures

  1. Skin Temperature [up to 90 days]

    Exploratory assessment of thermal skin measurements taken with the study device

  2. Acceleration [up to 90 days]

    Exploratory assessment of accelerometer measurements taken with the study device

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Existing ventriculoperitoneal CSF shunt

  2. Region of intact skin overlying an unambiguously identifiable chronically indwelling ventricular shunt which crosses the clavicle and is appropriate in size for application of the study device

  3. Available for remote and in-person follow-up during the 30-day measurement period (for subjects using the study device at home)

  4. Subject is expected to remain in an inpatient setting for sufficient time to complete all required study device measurements (for subjects using the device in an inpatient hospital setting)

  5. Signed informed consent by subject or a parent, legal guardian, health care agent, or surrogate decision maker (according to local statutes)

  6. Subject or caregiver is able to clearly communicate and document information and shunt symptoms in English

  7. Verbal assent by minors 12 years of age and older who are able to understand the study and communicate their decision

  8. Patient is at least 6 years old but not more than 80 years old

Exclusion Criteria:
  1. Presence of multiple shunts, or presence of more than one distal shunt catheter (regardless of function) crossing the clavicle ipsilateral to the shunt

  2. Shunt is not palpable due to depth or depth of shunt where the device will be placed is greater than 4 mm per ultrasound evolution.

  3. Presence of an interfering open wound or edema over any portion of the shunt

  4. Patient-reported history of adverse skin reactions to adhesives

  5. Investigator judges that the subject is likely to be lost to follow-up due to unavailability or clinical outcome being unobtainable

  6. Investigator judges that the subject is unlikely to successfully take reliable measurements at home (for subjects using the study device at home)

  7. Investigator judges that the subject/subject's caretaker would not be able to successfully place the device without assistance

  8. Use of the study device would interfere with standard patient care, or emergency surgery that cannot be delayed, or participation in the study will interfere with, or be detrimental to, administration of optimal healthcare to the subject

  9. Prior enrollment in this study

  10. Participation in any other investigational procedural, pharmaceutical, and/or device study that may influence the collection of valid data under this study

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Rhaeos, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rhaeos, Inc.
ClinicalTrials.gov Identifier:
NCT06086561
Other Study ID Numbers:
  • 2023-01
First Posted:
Oct 17, 2023
Last Update Posted:
Oct 17, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 17, 2023